New antithrombotic drugs for atrial fibrillation: Caution is needed

The Lancet

Volumn 379, Issue 9813, 2012, Pages

  Bell, Sarah ^a   Nand, Jessica ^b   Spriggs, David ^b  

^a AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DABIGATRAN; TROGLITAZONE; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DRUG DERIVATIVE; FIBRINOLYTIC AGENT; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

BLEEDING; DRUG APPROVAL; DRUG INDICATION; DRUG SAFETY; EUROPE; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; NEW ZEALAND; PRIORITY JOURNAL; NOTE;

BENZIMIDAZOLES; BETA-ALANINE; DRUG APPROVAL; FIBRINOLYTIC AGENTS; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; THIOPHENES;

EID: 84856382944     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60146-9     Document Type: Letter

References (4)

1. E Marijon, L Fauchier, J Le Heuzey New antithrombotic drugs and European approval process Lancet 378 2011 662 663
2. The Executive Steering Committee on behalf of the ROCKET-AF Study Investigators Rivaroxaban - once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET-AF study Am Heart J 159 2010 340 347
3. SJ Connolly, MD Ezekowitz, S Yusuf et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
4. EAM Gale Lessons from the glitazones: a story of drug development Lancet 357 2001 1870 1875 (Pubitemid 32539124)